For a patient with diastolic dysfunction and heart failure with preserved ejection fraction, chronic venous insufficiency, low ferritin (17.7 ng/mL) and low‑normal hemoglobin, preserved ejection fraction, a slowly rising E/e′ ratio of 9.2, normal left atrial volume index (22.1 mL/m²), and mild bilateral ankle pitting edema, is eplerenone 25 mg daily indicated and could it cause the ankle edema?

Eplerenone Is Not Indicated for Your Clinical Presentation and Is Unlikely to Cause Your Ankle Swelling

Based on current evidence-based guidelines, eplerenone 25 mg is not indicated for your clinical presentation of HFpEF with preserved ejection fraction, normal left atrial volume, and only mildly elevated E/e' ratio. The ankle edema you're experiencing is far more likely attributable to your chronic venous insufficiency and iron deficiency anemia than to the eplerenone.

Why Eplerenone Is Not Indicated in Your Case

Guideline-Based Indications for Aldosterone Antagonists

The established indications for eplerenone are highly specific and do not match your clinical profile:

• Heart failure with reduced ejection fraction (HFrEF): Eplerenone is indicated for patients with LVEF ≤35% and NYHA functional class III-IV symptoms (moderate to severe heart failure) 1.

• Post-myocardial infarction: Eplerenone is approved for patients with LVEF ≤40% within 3-14 days after acute MI with clinical evidence of heart failure or diabetes 2.

• Your clinical picture: You have a preserved ejection fraction (by definition >50%), which immediately excludes you from the evidence-based indications for aldosterone antagonists 1.

The HFpEF Evidence Gap

There is no proven mortality or morbidity benefit for aldosterone antagonists in HFpEF 1, 3. While one small trial (RAAM-PEF) with only 44 patients showed eplerenone improved some echocardiographic markers of diastolic function and reduced collagen turnover biomarkers, it failed to improve the primary endpoint of exercise capacity (6-minute walk distance) 4. This lack of functional benefit is critical because quality of life and functional capacity are paramount outcomes.

The 2023 ACC Expert Consensus on HFpEF management does not recommend aldosterone antagonists as standard therapy for HFpEF 1. Recent systematic reviews of HFpEF guidelines note that the role of spironolactone/eplerenone in HFpEF remains a gap in evidence with disagreement among guidelines 1.

Your Specific Clinical Parameters

Your echocardiographic findings actually suggest minimal diastolic dysfunction:

• E/e' ratio of 9.2: This is at the lower end of the abnormal range (normal is typically <8-10). While slowly rising, it remains only mildly elevated 1.

• Normal LAVI of 22.1 mL/m²: Left atrial enlargement (LAVI >34 mL/m²) is a key marker of chronic diastolic dysfunction and elevated filling pressures. Your normal LAVI argues against significant chronic diastolic dysfunction 1.

• Preserved ejection fraction: This excludes you from all evidence-based aldosterone antagonist indications 1, 2.

Eplerenone Is Unlikely to Be Causing Your Ankle Swelling

Mechanism of Action

Eplerenone is a mineralocorticoid receptor antagonist that blocks aldosterone, leading to:

• Potassium retention (risk of hyperkalemia) 1
• Mild diuretic effect through sodium and water excretion 1

Aldosterone antagonists do not typically cause peripheral edema—in fact, they have a mild diuretic effect that should theoretically reduce edema 1.

The Real Culprits for Your Ankle Swelling

Your ankle edema is far more likely due to:

1. Chronic venous insufficiency: This is a primary cause of bilateral ankle edema and is explicitly listed as a "noncardiac mimic" of heart failure congestion 1. Venous insufficiency causes fluid accumulation in the lower extremities independent of cardiac function.

2. Iron deficiency anemia: Your ferritin of 17.7 ng/mL indicates significant iron deficiency (normal is typically >30 ng/mL for women, >40 ng/mL for men). Iron deficiency can contribute to:

   • Reduced oxygen-carrying capacity
   • Compensatory fluid retention
   • Worsening of heart failure symptoms 1

3. Possible volume overload from HFpEF: While your diastolic parameters are only mildly abnormal, mild pitting edema can occur in HFpEF, particularly in the context of comorbidities 5, 6.

Clinical Evidence on Edema in HFpEF

A study analyzing 393 ambulatory HFpEF patients found that those with edema had higher body mass index, greater comorbidity burden, and more severe exercise intolerance, but the edema was related to the overall phenotype rather than specific medications 5. The presence of edema in HFpEF is often multifactorial, involving obesity, venous insufficiency, and renal dysfunction 5, 6.

Recommended Management Approach

1. Address the Iron Deficiency

Iron replacement is critical and may improve your symptoms more than any cardiac medication:

• Iron deficiency is common in heart failure and contributes to fatigue, exercise intolerance, and potentially fluid retention 1.
• Consider oral iron supplementation (if tolerated) or intravenous iron if oral therapy fails or is not tolerated 1.

2. Optimize Venous Insufficiency Management

• Compression stockings (20-30 mmHg graduated compression)
• Leg elevation when sitting or lying down
• Regular walking/exercise to promote venous return
• Consider evaluation by a vascular specialist if not already done

3. Diuretic Therapy for Symptomatic Relief

If ankle edema is bothersome:

• Low-dose loop diuretic (e.g., furosemide 20-40 mg daily) is the appropriate first-line therapy for symptomatic edema in HFpEF 1.
• Diuretics provide symptomatic relief but do not improve mortality in HFpEF 1.
• Use the lowest effective dose to avoid excessive diuresis, which can worsen renal function and activate neurohormonal systems 1.

4. Consider Discontinuing Eplerenone

Given that:

• You don't meet evidence-based indications for eplerenone 1, 2
• There's no proven benefit in HFpEF 1, 4, 3
• You have risk factors for hyperkalemia (low-normal hemoglobin, possible renal issues) 1

Discuss with your cardiologist whether continuing eplerenone is appropriate. The 2022 ESC review on polypharmacy in older cardiovascular patients specifically cautions about mineralocorticoid receptor antagonists, noting the risk of hyperkalemia increases with chronic kidney disease and requires careful monitoring 1.

5. Evidence-Based HFpEF Therapies

If you truly have symptomatic HFpEF, the only medication class with proven mortality/morbidity benefit is:

• SGLT2 inhibitors (empagliflozin or dapagliflozin): These are now recommended as first-line therapy for HFpEF based on recent trials 1, 7.

Important Monitoring Considerations

If eplerenone is continued despite lack of indication, mandatory monitoring includes 1:

• Serum potassium and creatinine at 1 and 4 weeks after starting, then at 1,2,3,6,9, and 12 months, then every 4 months 1.
• Stop eplerenone immediately if potassium >6.0 mmol/L or creatinine >3.5 mg/dL 1.
• Halve the dose if potassium 5.5-5.9 mmol/L or creatinine 2.5-3.5 mg/dL 1.

Common Pitfalls to Avoid

1. Assuming all heart failure medications work in HFpEF: Therapies proven effective in HFrEF (like aldosterone antagonists, ACE inhibitors, ARBs) have failed to show benefit in HFpEF 1, 3, 8, 9.

2. Attributing all edema to heart failure: In patients with multiple comorbidities, edema is often multifactorial. Your venous insufficiency is a primary cause that requires specific management 1, 5.

3. Ignoring iron deficiency: This is a treatable condition that significantly impacts quality of life and may worsen heart failure symptoms 1.

4. Over-diuresis in HFpEF: Excessive diuretic use can worsen renal function and reduce cardiac output in patients with HFpEF who are preload-dependent 1.